Craig-Hallum lowered the firm’s price target on Ironwood to $18 from $21 and keeps a Buy rating on the shares. The firm believes the negative reaction to apraglutide’s phase 3 readout is overdone and sees a very nice risk-reward post-data for investors, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IRWD:
- Ironwood reports ‘positive’ results from Phase III trial of apraglutide
- Jefferies biotechnology analysts hold an analyst/industry conference call
- Ironwood price target raised to $21 from $20 at Piper Sandler
- Ironwood price target raised to $18 from $15 at Capital One
- Ironwood sees FY24 revenue $435M-$455M, consensus $462.82M
